Provides tissue-based molecular profiling solutions (MI Profile). Offers blood-based molecular profiling solutions (Caris Assure). Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 23% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades 39% below its peak. The market has trimmed its expectations for the company.
Over the last 5 years, sales grew about 23% a year on average.
The company sells $812.0M a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 30 buys and 16 sells. Management buying with its own money is usually read as a good sign.
A loss of $538.0M against $812.0M in annual sales.
At the current pace of spending, the cash lasts about 1.5 years. After that, the company needs to find new money.
On our five-subject report card, CAI sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: CAI has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.